F Cervantes

Summary

Country: Spain

Publications

  1. ncbi request reprint Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation
    Francisco Cervantes
    Haematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Br J Haematol 120:500-4. 2003
  2. doi request reprint New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
    Francisco Cervantes
    Hematology Department, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Blood 113:2895-901. 2009
  3. doi request reprint Myelofibrosis: an update on current pharmacotherapy and future directions
    Francisco Cervantes
    University of Barcelona, Hospital Clinic, Hematology Department, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain
    Expert Opin Pharmacother 14:873-84. 2013
  4. doi request reprint Improving survival trends in primary myelofibrosis: an international study
    Francisco Cervantes
    Hospital Clinic, Institut d Investigacio Biomedica August Pi i Sunyer, University of Barcelona, Spain
    J Clin Oncol 30:2981-7. 2012
  5. doi request reprint Prognostication in primary myelofibrosis
    Francisco Cervantes
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Villarroel 170, Barcelona, Spain
    Curr Hematol Malig Rep 7:43-9. 2012
  6. ncbi request reprint Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients
    Francisco Cervantes
    Haematology Department, Institute of Haematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Br J Haematol 118:786-90. 2002
  7. doi request reprint Advances in the understanding and management of primary myelofibrosis
    Francisco Cervantes
    Hematology Department, IDIBAPS, University of Barcelona, Barcelona, Spain
    Curr Opin Oncol 23:665-71. 2011
  8. ncbi request reprint Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients
    Francisco Cervantes
    Haematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Br J Haematol 129:771-5. 2005
  9. ncbi request reprint Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature
    Francisco Cervantes
    Haematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Br J Haematol 127:399-403. 2004
  10. ncbi request reprint Assessment of neutrophil activation in whole blood by flow cytometry
    A Alvarez-Larran
    Hematology Department, Hospital Sant Joan de Deu, Barcelona, Spain
    Clin Lab Haematol 27:41-6. 2005

Detail Information

Publications67

  1. ncbi request reprint Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation
    Francisco Cervantes
    Haematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Br J Haematol 120:500-4. 2003
    ..Imatinib mesylate is effective and safe in chronic-phase CML patients with a previous history of intensive treatment...
  2. doi request reprint New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
    Francisco Cervantes
    Hematology Department, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Blood 113:2895-901. 2009
    ..JAK2V617F did not cluster with a specific risk group or affect survival...
  3. doi request reprint Myelofibrosis: an update on current pharmacotherapy and future directions
    Francisco Cervantes
    University of Barcelona, Hospital Clinic, Hematology Department, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain
    Expert Opin Pharmacother 14:873-84. 2013
    ..Discovery of the JAK2 mutation has provided the basis for the introduction of a new class of drugs, the JAK inhibitors, in the treatment of MF...
  4. doi request reprint Improving survival trends in primary myelofibrosis: an international study
    Francisco Cervantes
    Hospital Clinic, Institut d Investigacio Biomedica August Pi i Sunyer, University of Barcelona, Spain
    J Clin Oncol 30:2981-7. 2012
    ..This study was aimed at ascertaining whether survival prolongation has actually occurred in PMF...
  5. doi request reprint Prognostication in primary myelofibrosis
    Francisco Cervantes
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Villarroel 170, Barcelona, Spain
    Curr Hematol Malig Rep 7:43-9. 2012
    ....
  6. ncbi request reprint Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients
    Francisco Cervantes
    Haematology Department, Institute of Haematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Br J Haematol 118:786-90. 2002
    ..After a median the myelofibrotic transformation, three patients have died and four have not required treatment for MMM as yet...
  7. doi request reprint Advances in the understanding and management of primary myelofibrosis
    Francisco Cervantes
    Hematology Department, IDIBAPS, University of Barcelona, Barcelona, Spain
    Curr Opin Oncol 23:665-71. 2011
    ..We herein review the recent contributions to the understanding and management of PMF...
  8. ncbi request reprint Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients
    Francisco Cervantes
    Haematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Br J Haematol 129:771-5. 2005
    ..001) and higher Hb at treatment start (P= 0.02). Toxicity was usually moderate, leading to treatment withdrawal in only two cases. Danazol is effective and well tolerated in a substantial proportion of MMM patients with anaemia...
  9. ncbi request reprint Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature
    Francisco Cervantes
    Haematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Br J Haematol 127:399-403. 2004
    ..In the multivariate analysis, serum erythropoietin level <125 U/l was found to be associated with a favourable response to rHuEPO, whereas lack of transfusional support had borderline significance...
  10. ncbi request reprint Assessment of neutrophil activation in whole blood by flow cytometry
    A Alvarez-Larran
    Hematology Department, Hospital Sant Joan de Deu, Barcelona, Spain
    Clin Lab Haematol 27:41-6. 2005
    ..19%, P = 0.03). When compared with standard methods, neutrophil activation assessment by a no-lyse no-wash method resulted in lower neutrophil depletion and differences in oxidative burst and CD11b neutrophil values...
  11. pmc Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group
    Francisco Cervantes
    Hematology Department, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Haematologica 95:1317-24. 2010
    ..Despite the favorable results of imatinib front line in chronic-phase chronic myeloid leukemia there is room for improvement...
  12. ncbi request reprint Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia
    Francisco Cervantes
    Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Br J Haematol 134:184-6. 2006
    ..006). None of the patients with appropriate serum erythropoietin levels responded. Treatment was usually well tolerated...
  13. doi request reprint Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders
    F Cervantes
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Leukemia 22:905-14. 2008
    ..With regard to PMF, the possible association of the mutation with shorter survival and higher acute transformation rate is currently being evaluated...
  14. ncbi request reprint Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution
    F Cervantes
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Leukemia 20:55-60. 2006
    ..1% for those in cellular phase. These results indicate an increased thrombotic risk for IM patients with hyperproliferative features and/or coexistent cardiovascular risk factors...
  15. ncbi request reprint Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival
    F Cervantes
    Institute of Hematology and Oncology, Hematology Department, Postgraduate School of Hematology Farrreras Valentí, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Eur J Haematol 66:324-7. 2001
    ..These results indicate that in most young adults with MMM the disease presents without adverse prognostic factors and may remain stable for years, which may be of interest when considering the treatment of such patients...
  16. doi request reprint Practical management of patients with chronic myeloid leukemia
    Francisco Cervantes
    Hematology Department, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Cancer 117:4343-54. 2011
    ....
  17. ncbi request reprint Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon
    F Cervantes
    Hematology Department, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Haematologica 86:1281-6. 2001
    ..The objective of this study was to determine the efficacy and tolerance of IFN plus oral Ara-C ocfosfate (YNK-01) in IFN-resistant CML patients...
  18. ncbi request reprint Modern management of myelofibrosis
    Francisco Cervantes
    Haematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Br J Haematol 128:583-92. 2005
    ..The next candidates for the treatment of myelofibrosis are the thalidomide derivatives, the proteasome inhibitors, and vascular endothelial growth factor neutralizing antibodies...
  19. ncbi request reprint Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression
    S Montoto
    Department of Hematology and Hematopathology Unit, Hospital Clinic, IDIBAPS, Barcelona
    Ann Oncol 15:1484-9. 2004
    ..A new prognostic index specifically addressing FL patients, the Follicular Lymphoma International Prognostic Index (FLIPI), has recently been developed, which might also be useful in patients with progression...
  20. ncbi request reprint Danazol treatment of idiopathic myelofibrosis with severe anemia
    F Cervantes
    Department of Hematology, Hospital Clinic, University of Barcelona, Spain
    Haematologica 85:595-9. 2000
    ..The aim of the present study was to evaluate the effect of danazol on the anemia of IM...
  21. ncbi request reprint Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000
    F Cervantes
    Hematology Department, Hospital Clinic, Barcelona, Spain
    Pathol Biol (Paris) 49:148-52. 2001
    ..The role in MMM of newer treatment strategies such as autologous transplantation or the administration of anti-angiogenic drugs such as thalidomide is currently being evaluated...
  22. ncbi request reprint Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients
    A Alvarez-Larran
    Department of Hematology, Hospital del Mar, Barcelona, Spain
    Leukemia 21:1218-23. 2007
    ..Actuarial freedom from evolution to MF was 97% at 10 years. In conclusion, young ET patients have thrombotic events, especially stroke and venous thrombosis, more frequently than generally considered, whereas they rarely transform to MF...
  23. ncbi request reprint Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status
    J Esteve
    Institute of Hematology and Oncology, Department of Hematology, University of Barcelona, Spain
    Leukemia 15:445-51. 2001
    ..These results show that in CLL the probability of achieving sustained MRD(-) CR is higher with allogeneic than with autologous transplants, and confirm the value of MRD assessment in the follow-up of patients transplanted for CLL...
  24. ncbi request reprint Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis
    F Cervantes
    Institute of Hematology and Oncology, Hematology Department, IDIBAPS, Hospital Clinic, University of Barcelona, Spain
    Eur J Haematol 65:104-8. 2000
    ..We conclude that most IM patients have absolute lymphopenia, decreased T cells and increased cytotoxic T cells at diagnosis, and 10% of them show an increased CD5 + B-cell subpopulation...
  25. ncbi request reprint Hypercalcemia as the presenting feature of t-cell lymphoid blast crisis of ph-positive chronic myeloid leukemia
    E Nadal
    Institute of Hematology and Oncology, Hematology Department, Postgraduate School of Hematology Farreras Valenti, IDIBAPS, Hospital Clinic, University of Barcelona, Spain, Villarroel 170, 08036 Barcelona, Spain
    Leuk Lymphoma 41:203-6. 2001
    ..Coincidentally, a high proportion of blast cells of T-cell origin at the cortical thymocyte stage were observed in the patient's peripheral blood and bone marrow, and she died shortly afterwards...
  26. ncbi request reprint Survival after progression in patients with follicular lymphoma: analysis of prognostic factors
    S Montoto
    Department of Hematology, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain
    Ann Oncol 13:523-30. 2002
    ..These would be useful for selection of high-risk patients for inclusion in trials aimed at determining the effect of new treatment approaches in such patients...
  27. ncbi request reprint Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia
    Jose Roman-Gomez
    Hematology Department, Reina Sofia Hospital, Avda Menendez Pidal s n 14004, Cordoba, Spain
    Oncogene 24:7213-23. 2005
    ..005). The above results strongly suggest that activation of both sense and antisense transcriptions by aberrant promoter hypomethylation of the L1 elements plays a role in the progression and clinical behavior of the CML...
  28. ncbi request reprint Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia
    Dolors Costa
    Hematopathology Unit, Hospital Clinic Villarroel, 170, 08036, Barcelona, Catalonia, Spain
    Cancer Genet Cytogenet 166:89-93. 2006
    ..In conclusion, FISH studies have been useful in the detection of the BCR/ABL rearrangements and 9q34 deletions, and to identify complex rearrangements that differ from the ones previously established by conventional cytogenetics...
  29. ncbi request reprint Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia
    Dolors Costa
    Unitat Hematopatologia, Hospital del Mar, Barcelona, Spain
    Cancer Genet Cytogenet 141:114-9. 2003
    ..In conclusion, in cases of Ph- CML, FISH studies are of paramount importance since they can detect chromosomal reorganization and its location, and can also provide quantitative follow-up of these patients...
  30. ncbi request reprint Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia
    Jose Roman-Gomez
    Hematology Department, Reina Sofia Hospital, Avda Menendez Pidal s n 14004 Cordoba, Spain
    Haematologica 92:153-62. 2007
    ..To date, CTA genes have been shown to be expressed in a range of solid tumors via demethylation of their promoter CpG islands, but rarely in chronic myeloid leukemia (CML) or other hematologic malignancies...
  31. ncbi request reprint Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients
    Francisco Cervantes
    Hematology Department, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Haematologica 88:1117-22. 2003
    ..The results of imatinib treatment in chronic-phase CML patients resistant or intolerant to interferon (IFN) and the factors predicting therapeutic response and progression-free survival were analyzed...
  32. ncbi request reprint Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon
    Juan Carlos Hernández-Boluda
    BMT Unit, Institute of Hematology and Oncology, Department of Hematology, Hospital del Mar, Villaroel 170, 08036 Barcelona, Spain
    Haematologica 87:17-22. 2002
    ..The results of using recombinant human granulocyte colony-stimulating factor (rHuG-CSF) for harvesting hematopoietic progenitors in CML patients treated with interferon-a (IFN) are reported...
  33. ncbi request reprint Idiopathic myelofibrosis associated with primary biliary cirrhosis
    J C Hernández-Boluda
    Department of Hematology, Institute of Hematology and Oncology, Postgraduate School of Hematology Farreras Valenti, IDIBAPS, Hospital Clinic, University of Barcelona, Villarroel, Spain
    Leuk Lymphoma 43:673-4. 2002
    ..This case represents a new association of IM with an autoimmune disease, supporting the hypothesis of a possible immune basis of IM in some cases...
  34. ncbi request reprint Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia
    J C Hernández-Boluda
    Department of Hematology, Postgraduate School of Hematology Farreras Valenti, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Ann Hematol 80:516-20. 2001
    ..2-12, respectively). These results indicate that 6-MP therapy constitutes a good palliative treatment for patients with nonlymphoid BC of CML. However, new treatment strategies for this hematological condition are required...
  35. ncbi request reprint Successful treatment by selective arterial embolization of severe retroperitoneal hemorrhage secondary to bone marrow biopsy in post-polycythemic myelofibrosis
    E Arellano-Rodrigo
    Hematology Department, Institute of Hematology and Oncology, Postgraduate School of Hematology Farreras Valenti, IDIBAPS, Hospital Clinic, Villarroel, 170, 08036 Barcelona, Spain
    Ann Hematol 83:67-70. 2004
    ..This case illustrates the effectiveness of an endovascular approach in providing a fast and minimally invasive treatment for this life-threatening complication of bone marrow trephine biopsy...
  36. ncbi request reprint Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia
    Monica Pou
    Nephrology Department, Hospital Clinic, Barcelona, Spain
    Leuk Lymphoma 44:1239-41. 2003
    ..One year later the patient still has mild chronic renal failure and remains in chronic phase of CML on hydroxyurea treatment...
  37. ncbi request reprint New and old treatment modalities in primary myelofibrosis
    Francisco Cervantes
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Cancer J 13:377-83. 2007
    ..Newer immunomodulatory drugs, proteasome inhibitors, hypomethylating agents, and JAK2 inhibitors are currently being tested...
  38. ncbi request reprint Relationship among densitometry, bone histomorphometry, and histologic stage in idiopathic myelofibrosis
    L Mellibovsky
    Department of Internal Medicine and Metabolic Unit, Hospital Universitari del Mar, Autonomous University of Barcelona, Barcelona, Spain
    Bone 34:330-5. 2004
    ..This balance would produce the increase in bone mass observed in this disease. Given the increase in BMD observed with more advanced stages of IMF, this noninvasive method could be useful tool for assessing IMF progression...
  39. ncbi request reprint Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging
    Francisco Cervantes
    Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Semin Oncol 32:395-402. 2005
    ..Such a staging system should be derived from a large population of patients, systematically collected from diagnosis without selection bias and followed over time...
  40. ncbi request reprint Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients
    Juan Carlos Hernández-Boluda
    Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Exp Hematol 31:204-10. 2003
    ..The aim of this study was to contribute to a better knowledge of the status of such locus in the different phases of CML and to analyze the prognostic significance of its inactivation...
  41. ncbi request reprint Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa
    Jose Roman-Gomez
    Hematology Department, Reina Sofia Hospital, Avda, Menendez Pidal s n, 14004 Cordoba, Spain
    J Clin Oncol 21:1472-9. 2003
    ..Although defective progenitor-stromal adhesion is a well-recognized feature of chronic myeloid leukemia (CML), the role of CDH13 abnormalities has not been evaluated in this disease...
  42. ncbi request reprint Idiopathic myelofibrosis associated with classic polyarteritis nodosa
    Mireia Camos
    Institute of Hematology and Oncology, Department of Hematology, Postgraduate School of Hematology Farreras Valenti, Hospital Clinic, Villarroel 170, University of Barcelona, Barcelona, 08036 Spain
    Leuk Lymphoma 44:539-41. 2003
    ..This case represents a new association between IM and an autoimmune disease and supports the hypothesis of an immune basis of IM in some patients...
  43. ncbi request reprint Idiopathic myelofibrosis associated with ulcerative colitis
    Eduardo Arellano-Rodrigo
    Institute of Hematology and Oncology, Department of Hematology, Postgraduate School of Hematology Farreras Valenti, Barcelona, Spain
    Leuk Lymphoma 43:1481-3. 2002
    ..The present case represents a new association of IM with an autoimmune disease and gives support to the hypothesis of a possible immune basis of some IM cases...
  44. ncbi request reprint Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis
    Alberto Alvarez-Larran
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Ann Hematol 87:269-76. 2008
    ..In conclusion, PMF patients have platelet, leukocyte, endothelial, and coagulation activation similar to that in PV and ET. CD11b overexpression and F1 + 2 are correlated with the presence of the JAK2 mutation...
  45. ncbi request reprint The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha
    Jose Roman-Gomez
    Hematology Department, Reina Sofia Hospital, Cordoba, Spain
    Haematologica 89:42-8. 2004
    ..Because suppressor of cytokine signaling (SOCS) proteins are negative regulators of cytokine-induced signaling, it has been hypothesized that aberrant SOCS expression could confer resistance against cytokine therapy...
  46. doi request reprint Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
    Alberto Alvarez-Larran
    Hematology Department, Hospital del Mar, Barcelona, Spain
    Blood 116:1205-10; quiz 1387. 2010
    ..In the remaining low-risk patients, this therapy is not effective as primary prophylaxis of thrombosis, and observation may be an adequate option...
  47. ncbi request reprint Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients
    Juan Carlos Hernández-Boluda
    Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Leuk Lymphoma 46:717-22. 2005
    ..However, further studies are required to elucidate the possible prognostic importance of such biological findings in this disease...
  48. ncbi request reprint Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status
    Eduardo Arellano-Rodrigo
    Hematology Department, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Haematologica 91:169-75. 2006
    ..The aim of the present study was to ascertain the role of platelet and leukocyte activation in the thrombosis of ET...
  49. ncbi request reprint JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis
    Luz Martínez-Avilés
    Department of Pathology, Hospital del Mar, IMAS, Barcelona, Spain
    Haematologica 92:1717-8. 2007
    ..Initial hematologic data of these patients differ from those of V617F-positive patients, but there is no difference in thrombotic development and myelofibrotic transformation...
  50. ncbi request reprint Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 110:1092-7. 2007
    ....
  51. pmc Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3500-7. 2008
    ..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT...
  52. ncbi request reprint Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 110:3540-6. 2007
    ..In summary, nilotinib is highly active and safe in patients with CML-CP after imatinib failure or intolerance. This clinical trial is registered at http://clinicaltrials.gov as ID no. NCT00109707...
  53. ncbi request reprint Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and
    Ruben A Mesa
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:737-40. 2007
    ....
  54. ncbi request reprint Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera
    Alberto Alvarez-Larran
    Haematology Department, Institute of Haematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Br J Haematol 124:329-35. 2004
    ..05). These results support a role for neutrophils in BCS/PVT secondary to PV and indicate that neutrophil CD11b expression could be of use for PV screening in BCS/PVT patients...
  55. ncbi request reprint Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib
    Feng Lin
    Blood 102:1143. 2003
  56. ncbi request reprint International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
    Ayalew Tefferi
    Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
    Blood 108:1497-503. 2006
    ..Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly...
  57. ncbi request reprint Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Blood 108:1809-20. 2006
    ..The importance of regular monitoring at experienced centers was highlighted...
  58. ncbi request reprint Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    Stephen G O'Brien
    University of Newcastle, Newcastle, United Kingdom
    N Engl J Med 348:994-1004. 2003
    ..We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML...
  59. ncbi request reprint Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
    Andreas Hochhaus
    III Medizinische Klinik, Medizinische Fakultat Mannheim, Universitat Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    Blood 109:2303-9. 2007
    ..This trial was registered at www.clinicaltrials.gov as CA180013...
  60. ncbi request reprint Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Brian J Druker
    Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    N Engl J Med 355:2408-17. 2006
    ..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy...
  61. ncbi request reprint Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies
    Juan Carlos Hernández-Boluda
    Hematology and Medical Oncology Department, Hospital Clinico Universitario, Valencia, Spain
    Drugs Today (Barc) 38:601-13. 2002
    ..In this sense, it must be pointed out that imatinib has shown a remarkable activity in gastrointestinal stromal tumors...
  62. ncbi request reprint TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy
    Antonia Perello
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, University of Barcelona, Barcelona, Catalunya, Spain
    Hepatology 35:132-9. 2002
    ..In conclusion, in patients with BCS uncontrolled with medical therapy, TIPS is a highly effective technique that is associated with long-term survival...
  63. ncbi request reprint Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Blood 106:2849-53. 2005
    ..A histologic response was defined by changes in bone marrow fibrosis and cellularity grades. The combined use of these response definitions should help standardize the design and reporting of future clinical studies in MMM...
  64. ncbi request reprint Portal hypertension secondary to myelofibrosis: a study of three cases
    Alberto Alvarez-Larran
    Hematology Department, Azienda Ospedaliero Universitaria di Careggi, Firenze, Italy
    Am J Gastroenterol 100:2355-8. 2005
    ..In patients with idiopathic myelofibrosis (IM), portal hypertension (PHT) without thrombosis of the hepatic or splenoportal veins is infrequent...
  65. doi request reprint The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
    Jean Jacques Kiladjian
    Assistance Publique Hopitaux de Paris, Hopital Avicenne, Service d Hematologie Clinique, and Université Paris 13, Bobigny, France
    Blood 111:4922-9. 2008
    ..Underlying MPD is associated with severe forms of BCS, but current therapy appears to offset deleterious effects of MPD on the medium-term outcome...
  66. ncbi request reprint Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options
    Ruben A Mesa
    Laboratory of Clinical Epidemiology, IRCCS Policlinico S Matteo, Pavia, Italy
    Best Pract Res Clin Haematol 19:495-517. 2006
    ..Modern therapy remains palliative but allogeneic stem cell transplantation might be curative to a selected group of patients. This chapter reviews both the old and the new therapy with regard to non-transplant treatment options for MMM...
  67. ncbi request reprint Late response to donor lymphocyte infusions in patients with chronic myeloid leukemia relapsing after allogeneic stem cell transplantation
    Marta Gomez
    Haematologica 87:1003-5. 2002
    ..The median time (range) in months to achieve a hematologic, cytogenetic and molecular remission was 2 (1-2), 5 (1-42) and 5 the median response duration is 16 months (range 1-36), and no patient shows evidence of relapse...